Activation of PAF-receptor induces regulatory dendritic cells through PGE2 and IL-10

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 89, Issue 5, 2013, Pages 319-326

  Koga, Marianna M ^a   Bizzarro, Bruna ^a   Sá Nunes, Anderson ^a   Rios, Francisco J O ^a   Jancar, Sonia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antigen presentation; DC; IL 10; PAF; PGE2

Indexed keywords

1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID METHYL 2 PHENYLTHIOETHYL ESTER; APAFANT; B7 ANTIGEN; BEPAFANT; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLOOXYGENASE 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PROSTAGLANDIN E2; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

MURINAE;

ANTIGEN-PRESENTATION; DC; IL-10; PAF; PGE(2);

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; BONE MARROW CELLS; CELL DIFFERENTIATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DENDRITIC CELLS; DINOPROSTONE; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-10; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; PRIMARY CELL CULTURE; RECEPTORS, CCR7; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84886946217     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.09.003     Document Type: Article

References (33)

1. Honda Z., Ishii S., Shimizu T. Platelet-activating factor receptor. J. Biochem. 2002, 131:773-779.
2. Ishii S., Nagase T., Shimizu T. Platelet-activating factor receptor. Prostaglandins Other Lipid Mediat. 2002, 68-69:599-609.
3. Fadok V.A., Bratton D.L., Konowal A., Freed P.W., Westcott J.Y., Henson P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 1998, 101:890-898.
4. Freire-de-Lima C.G., Xiao Y.Q., Gardai S.J., Bratton D.L., Schiemann W.P., Henson P.M. Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 2006, 281:38376-38384.
5. Bachi A.L., Dos Santos L.C., Nonogaki S., Jancar S., Jasiulionis M.G. Apoptotic cells contribute to melanoma progression and this effect is partially mediated by the platelet-activating factor receptor. Mediat. Inflamm. 2012, 2012:610371.
6. Walterscheid J.P., Ullrich S.E., Nghiem D.X. Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J. Exp. Med. 2002, 195:171-179.
7. Sahu R.P., Turner M.J., DaSilva S.C., Rashid B.M., Ocana J.A., Perkins S.M., Konger R.L., Touloukian C.E., Kaplan M.H., Travers J.B. The environmental stressor ultraviolet B radiation inhibits murine antitumor immunity through its ability to generate platelet-activating factor agonists. Carcinogenesis 2012, 33:1360-1367.
8. Sahu R.P., Petrache I., Van Demark M.J., Rashid B.M., Ocana J.A., Tang Y., Yi Q., Turner M.J., Konger R.L., Travers J.B. Cigarette smoke exposure inhibits contact hypersensitivity via the generation of platelet-activating factor agonists. J. Immunol. 2013, 190:2447-2454.
9. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
10. Pulendran B., Palucka K., Banchereau J. Sensing pathogens and tuning immune responses. Science 2001, 293:253-256.
11. Sozzani S., Longoni D., Bonecchi R., Luini W., Bersani L., D'Amico G., Borsatti A., Bussolino F., Allavena P., Mantovani A. Human monocyte-derived and CD34+ cell-derived dendritic cells express functional receptors for platelet activating factor. FEBS Lett. 1997, 418:98-100.
12. Dichmann S., Rheinen H., Panther E., Herouy Y., Czech W., Termeer C., Simon J.C., Gebicke-Haerter P.J., Norgauer J. Downregulation of platelet-activating factor responsiveness during maturation of human dendritic cells. J. Cell. Physiol. 2000, 185:394-400.
13. Angeli V., Llodrá J., Rong J.X., Satoh K., Ishii S., Shimizu T., Fisher E.A., Randolph G.J. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004, 21:561-574.
14. Lutz M.B., Kukutsch N., Ogilvie A.L., Rössner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999, 223:77-92.
15. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
16. Strassmann G., Patil-Koota V., Finkelman F., Fong M., Kambayashi T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J. Exp. Med. 1994, 180:2365-2370.
17. Jakobsson P.J., Thorén S., Morgenstern R., Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA 1999, 96:7220-7225.
18. Aronoff D.M., Canetti C., Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J. Immunol. 2004, 173:559-565.
19. Dent G., Ukena D., Chanez P., Sybrecht G., Barnes P. Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086. Correlation between receptor binding and function. FEBS Lett. 1989, 244:365-368.
20. Ortega M.P., García M.C., Gijón M.A., de Casa-Juana M.F., Priego J.G., Sanchez Crespo M., Sunkel C. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies. J. Pharmacol. Exp. Ther. 1990, 255:28-33.
21. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010, 10:170-181.
22. Alvarez Y., Municio C., Alonso S., Sánchez Crespo M., Fernández N. The induction of IL-10 by zymosan in dendritic cells depends on CREB activation by the coactivators CREB-binding protein and TORC2 and autocrine PGE2. J. Immunol. 2009, 183:1471-1479.
23. Kambayashi T., Jacob C.O., Zhou D., Mazurek N., Fong M., Strassmann G. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 1995, 155:4909-4916.
24. Harizi H., Juzan M., Pitard V., Moreau J.F., Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J. Immunol. 2002, 168:2255-2263.
25. Lukashova V., Asselin C., Krolewski J.J., Rola-Pleszczynski M., Stanková J. G-protein-independent activation of Tyk2 by the platelet-activating factor receptor. J. Biol. Chem. 2001, 276:24113-24121.
26. Deo D.D., Axelrad T.W., Robert E.G., Marcheselli V., Bazan N.G., Hunt J.D. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J. Biol. Chem. 2002, 277:21237-21245.
27. Labeur M.S., Roters B., Pers B., Mehling A., Luger T.A., Schwarz T., Grabbe S. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 1999, 162:168-175.
28. Rios F.J., Koga M.M., Ferracini M., Jancar S. Co-stimulation of PAFR and CD36 is required for oxLDL-induced human macrophages activation. PLoS One 2012, 7:e36632.
29. Honda A., Sugimoto Y., Namba T., Watabe A., Irie A., Negishi M., Narumiya S., Ichikawa A. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J. Biol. Chem. 1993, 268:7759-7762.
30. Regan J.W., Bailey T.J., Pepperl D.J., Pierce K.L., Bogardus A.M., Donello J.E., Fairbairn C.E., Kedzie K.M., Woodward D.F., Gil D.W. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol. 1994, 46:213-220.
31. Nishigaki N., Negishi M., Ichikawa A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol. 1996, 50:1031-1037.
32. Obermajer N., Muthuswamy R., Lesnock J., Edwards R.P., Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011, 118:5498-5505.
33. Weinlich R., Bortoluci K.R., Chehab C.F., Serezani C.H., Ulbrich A.G., Peters-Golden M., Russo M., Amarante-Mendes G.P. TLR4/MYD88-dependent, LPS-induced synthesis of PGE2 by macrophages or dendritic cells prevents anti-CD3-mediated CD95L upregulation in T cells. Cell Death Differ. 2008, 15:1901-1909.